Physician

Christopher Michael Webber, M.D.

According to 2025 Medicare claims, Christopher Webber, M.D. (NPI: 1386632172) practices allergy/immunology in the Colorado Springs, CO market, with the plurality of this provider's patient population coming from El Paso, CO. This provider's primary affiliated billing organization is PIKES PEAK ENT (NPI: 1467829309; TIN: 47-2632065) and primary practice location at 80920-7919.

Webber's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 225 traditional Medicare patients, billed 58,581 HCPCS/CPT codes, and received $1,011,385 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,482 prescription claims across 408 beneficiaries totaling $664,481 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 122 claims. Open Payments data shows 63 records totaling $24,863. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $4,780 to $1,011,385. Similarly, Part D prescription costs have moved sharply higher in recent years, from $2,541 to $664,481. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $980 to $5,868.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	15	439	$4,780
2016	25	928	$7,607
2017	97	4,509	$74,689
2018	234	6,892	$283,962
2019	266	7,082	$376,463
2020	184	6,777	$376,326
2021	181	6,049	$224,444
2022	185	10,401	$382,228
2023	208	45,845	$896,743
2024	225	58,581	$1,011,385

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	11	40	$2,541
2016	25	70	$7,946
2017	105	422	$41,125
2018	201	955	$132,094
2019	262	1,445	$265,431
2020	262	1,568	$322,402
2021	255	1,575	$493,712
2022	284	1,721	$431,693
2023	339	2,069	$551,773
2024	408	2,482	$664,481

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	12	$351
2018	N/R	N/R	N/R
2019	N/R	38	$81,456
2020	N/R	60	$177,141
2021	N/R	39	$145,909
2022	N/R	34	$133,293
2023	N/R	22	$93,955
2024	N/R	122	$190,606

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	125	231	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	100	139	$66
94010	Test to measure expiratory airflow and volume	91	178	$21
96372	Injection of drug or substance under skin or into muscle	77	435	$12
95004	Test for allergy using allergenic extract	70	4,237	$3

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	231	12,576	$265,932
Xolair	Omalizumab	24	672	$143,553
Dupixent Pen	Dupilumab	20	560	$77,617
Spiriva Respimat	Tiotropium Bromide	24	1,140	$17,883
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	21	690	$17,469

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1575	Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin	N	N/R	23	$116,706
J1576	Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	14	$63,111
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	17	$5,595
E0781	Ambulatory infusion pump, single or multiple channels, electric or battery operated, with administrative equipment, worn by patient	Y	N/R	21	$3,898
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)	N	N/R	23	$837

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	63	$24,863	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Christopher Michael Webber, M.D.?

Tedicare shows public-source Medicare data for Christopher Michael Webber, M.D. (NPI 1386632172), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Christopher Michael Webber, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Christopher Michael Webber, M.D.?

Christopher Michael Webber, M.D. is linked to PIKES PEAK ENT (billing NPI 1467829309) in the available physician profile data.

Does Christopher Michael Webber, M.D. have Open Payments data?

Christopher Michael Webber, M.D. has 63 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.